WO2024256657A1 - Endoprothèse pour implantation - Google Patents

Endoprothèse pour implantation Download PDF

Info

Publication number
WO2024256657A1
WO2024256657A1 PCT/EP2024/066599 EP2024066599W WO2024256657A1 WO 2024256657 A1 WO2024256657 A1 WO 2024256657A1 EP 2024066599 W EP2024066599 W EP 2024066599W WO 2024256657 A1 WO2024256657 A1 WO 2024256657A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
struts
elements
barbs
valve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/066599
Other languages
German (de)
English (en)
Inventor
Boris Schmitt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Charite Universitaetsmedizin Berlin
Original Assignee
Charite Universitaetsmedizin Berlin
Charite Universitaetsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin Berlin, Charite Universitaetsmedizin Berlin filed Critical Charite Universitaetsmedizin Berlin
Priority to AU2024305156A priority Critical patent/AU2024305156A1/en
Priority to CN202480039902.8A priority patent/CN121358508A/zh
Publication of WO2024256657A1 publication Critical patent/WO2024256657A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148—Materials at least partially resorbable by the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418—Scaffolds therefor, e.g. support stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/02—Inorganic materials
    • A61L31/022—Metals or alloys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials

Definitions

  • the present invention relates to stents for implantation, also comprising a heart valve-bearing stent, intended in particular for implantation in children.
  • Congenital heart defects affect an estimated one in every 100 newborns. These heart defects can vary in severity and therefore affect different structures of a newborn's heart. Treatment for congenital heart defects depends on the type and severity of the defect present. Some affected infants and children may require one or more operations to enable the heart or blood vessels to function properly.
  • stent refers to vascular prostheses or "supports” that are inserted by means of an intervention, for example to widen narrowed vessels. Stents are also used to anchor heart valves in the vascular system. Due to a lack of products suitable for children, permanent, non-resorbable stents are currently used, which were developed for adult patients.
  • Nitinol has the characteristic properties of pseudoelasticity and the shape memory effect.
  • Balloon-expandable stents can be dilated after implantation in a growing child, so that an increase in diameter is achieved. Dilation is not always possible (depending on the ingrowth behavior and the location of the stent). In some cases, the surrounding structures are injured or torn during dilation. Self-expanding stents are not dilated; They usually open almost to their specified final diameter depending on their radial force and the ambient pressure of the vessel counteracting the radial force.
  • WO 2011/000354 A2 discloses a stent into which a heart valve has been sewn, which consists of a plurality of crown elements arranged coaxially one behind the other, each of which is formed from several U-shaped arches with at least one base and two ends.
  • the bases of a crown element are connected to the ends of a crown element via connecting webs.
  • a 3-D droplet dosing technique is used to form a thin-walled sandwich structure.
  • the invention further relates to a device suitable for applying a stent with positioning wires that have clamps at their ends that can be connected in a force-fitting manner to the fixing hooks of the ends of the crown elements.
  • the published international patent application with the reference WO 2016/071357 A1 relates to an intraluminal vascular implant, with a first hollow cylindrical vascular body and at least one second hollow cylindrical vascular body, wherein the first and the second vascular body are two structurally separate vascular bodies.
  • the vascular bodies each have a first end, a second end and a longitudinal axis, wherein the first and the second vascular body each have vascular sections.
  • the vascular section of the first vascular body and the vascular section of the second vascular body are designed such that they can be at least partially inserted into each other to form a common stent section free of prosthetic material.
  • WO 2016/055564 A1 describes a vascular prosthesis system for introducing into and supporting a patient's blood vessel, the vascular prosthesis system comprising (i) a stent graft element with a hollow cylindrical body, the stent graft element having meandering supports and a prosthetic material attached to and connecting the supports to form a circumferentially covered stent graft element, and (ii) a stent element with a hollow cylindrical body, the stent element having a stent support structure that is free of prosthetic material to form an uncovered stent element.
  • a strip-shaped prosthetic material section is provided, via which the stent graft element and the stent element are connected to one another, such that the strip-shaped prosthetic material section is fixed with a first end only to the first, proximal stent graft element end and with its second end to the first, proximal stent element end to form a prosthetic material bridge.
  • the published international patent application with the reference WO 2000/062708 A1 relates to a multi-part stent comprising a connecting structure that allows the stent sections to move and bend relative to one another.
  • the connecting structure connects the multiple stent sections and keeps the stent sections substantially stationary relative to one another.
  • the connecting structure allows the multiple stent sections to move relative to one another.
  • the movable stent sections allow the stent to bend when deployed in a body lumen. This flexible structure allows the stent to better conform to the shape of the body lumen and exerts less pressure on the lumen wall overall, thereby reducing the risk of trauma.
  • the various stent sections can be completely detached from one another.
  • the stent sections can remain partially connected so that they can move largely independently of one another.
  • the connecting structure can be designed to separate upon deployment, e.g. by rupture or degradation within the body lumen in which the stent is positioned.
  • the published international patent application with the file number WO 2019/052610 A1 relates to an implantable valve prosthesis, in particular for preventing blood from flowing back from an atrium into a vein flowing into the atrium.
  • the object of the present invention is to provide an alternative to the previously available means for treating mitral valve or tricuspid valve insufficiency.
  • an implantable valve prosthesis comprising - a generally tubular stent, which can be branched or unbranched and has at least a first end section with a first end opening and a second end section with a second end opening, and - a flexible tube, which can be branched or unbranched and has at least a first end section with a first end opening and a second end section with a second end opening that can be closed by collapsing the tube, which is arranged at least in a partial region of the second end section of the stent on its outer peripheral surface such that the tube with its second end section and the second end opening protrudes beyond the second end opening of the stent, wherein the second end opening of the tube is open in the depressurized state.
  • the published German patent application with the reference DE 4222 610 A1 describes a stent for valve and closing elements, in particular for heart valve prostheses, which has a base ring which carries at least two posts which are symmetrically offset from one another, point essentially in the direction of the ring axis and are connected to one another via arched strips serving to attach at least two flexible leaflets, with which a valve or closing element, in particular a heart valve prosthesis, can be produced which also works reliably with different closing pressure differences, i.e.
  • the stent is only kept flexible in certain areas and to a limited extent, namely by a rigid design of the free post ends and/or a stop-limited flexibility of the post bases and/or a stop-limited flexibility of the strips.
  • US 2009/0312834 Al relates to stent structures with improved migration resistance.
  • US 2009/0312834 Al relates to Mesh stents, such as braided or twisted stents, in which at least a portion of the stent is folded back upon itself to form a multi-layered stent device.
  • Such multi-layered sections provide migration resistance, among other advantages.
  • bioabsorbable scaffold consisting at least in part of a poly(L-lactide)-based composite.
  • the composite contains poly(4-hydroxybutyrate) or poly(L-lactide)-b-polycaprolactone block copolymer, which increases the fracture toughness or fracture strength of the scaffold.
  • the composite may also contain bioceramic particles, L-lactide monomer, or both, distributed throughout the composite. The bioceramic particles improve the radial strength and stiffness of the scaffold.
  • the L-lactide monomer is used to control the absorption rate of the scaffold.
  • the published international application WO 2016/127542 A1 discloses a multilayered, expandable vascular scaffold having at least two layers of lattice-like scaffold walls made of a magnesium alloy and a scaffold interior cavity. An expandable balloon is arranged within the scaffold interior. During expansion of the multilayered expandable vascular scaffold, the scaffold wall near the outer layer exceeds its strain rate and breaks due to the relatively large expansion.
  • the vascular scaffold is prevented from breaking and losing the scaffold function caused by the breakage of the outer layer during expansion. Breakage of the outer layer during expansion, and safety is also improved.
  • valve prostheses with mechanically coupled leaflet valves.
  • the embodiments described in this document are directed to centrally opening valve prostheses with a valve frame and a mechanically coupled valve.
  • the valve frames described have projections that are configured to be connected to a valve attachment area of a valve.
  • Some embodiments include a valve holding device that engages the projections of the valve frame and serves to attach the valve to the valve frame. A method for making and using such valve prostheses is also described.
  • the published German patent application DE 10 2008 040 786 A1 describes an implant with a base body which consists entirely or in part of a biocorrodible, metallic material, wherein the material is such that it is decomposed to an alkaline product in an aqueous environment and wherein the base body has a coating or a cavity filling which comprises a polymer matrix and at least one active ingredient embedded in the polymer matrix, characterized in that at least one polymer of the matrix and the at least one active ingredient are coordinated with one another in such a way that the release rate of the active ingredient from the matrix is increased with increasing pH.
  • the published American patent application US 2011/060401 A1 relates to a tubular, growth-capable support prosthesis with a mesh structure, wherein the mesh structure consists of at least two structural rings which are connected to one another via connecting elements and are arranged point-symmetrically around the longitudinal axis of the prosthesis, wherein the structural rings and/or the connecting elements have at least one predetermined breaking point.
  • the published American patent application US 2013/325102 A1 discloses an absorbable blood vessel stent which has a proximal end and a distal end. A tubular structure with a pattern is formed between the proximal end and the distal end.
  • the patterned structure comprises a plurality of support and connecting rods.
  • the support rod or the connecting rod has a straight, a U-shaped or an S-shaped section, and at least one through groove or a through hole is provided in at least one support rod. Due to the special structure of the blood vessel stent, the performance of a blood vessel stent made of iron can be improved, and blood vessel stents made of other absorbable materials can be decomposed more quickly.
  • a permanent stent is particularly disadvantageous for the implantation of heart valves in children, since it is even more difficult to post-dilate than a non-valve balloon-expandable stent due to the heart valve located in the stent.
  • the heart valve could be damaged during post-dilation because the heart valve tissue would be squeezed between the high-pressure balloon and the stent.
  • the object of the present invention therefore relates to the provision of a stent for vascular supply, in which the absorption time of the biodegradable stent can be adjusted so that growth of the vessels is not hindered.
  • a stent is to be used in particular in newborns and children.
  • the present invention discloses a biodegradable, resorbable stent comprising a framework consisting of a metal alloy of magnesium with transition metals and/or rare earths, wherein the framework is coated with a polymer and the coated framework has struts of stent elements.
  • the stent elements are diamond-shaped.
  • One embodiment of the stent relates to a stent in which the struts are flattened.
  • the struts of the stent elements are slotted.
  • the rare earths are selected from the group of lanthanides, comprising gadolinium, disprosium, yttrium.
  • the struts of a stent according to the present disclosure may have barbs.
  • the circumference has 24, 21, 18, 15 or 12 stent elements.
  • the invention also relates to an embodiment of the stent, wherein the barbs have a diameter of up to 20 to 50 pm.
  • the barbs of a stent according to the present invention may be bent inwardly at an angle between 45° to 90° with respect to the struts of the stent.
  • the polymer of the sheath is biodegradable, wherein the polymer is poly(DL-lactide-co-glycolide).
  • one embodiment is a valve-bearing stent.
  • the circumference of the framework has a number of stent elements divisible by 3, wherein the framework has 24, 21, 18, 15 or 12 stent elements.
  • the heart valves are attached to the barbs of the struts.
  • Another object of the present invention relates to a system for implanting a stent comprising a device for implanting a stent as described above.
  • the present invention relates to the use of a stent as described above without valves, or of a system as described above, for implanting the stent in cases of congenital heart defects for opening a pulmonary artery, for keeping open a ductus arteriosus Botalli, for keeping open an aortic isthmus stenosis to create a growth stimulus in hypoplastic pulmonary arteries, or as an esophageal stent, or as a ureter support.
  • FIG. 1 shows a schematic overview of an embodiment of the structure of a stent according to the invention.
  • FIG. 2 schematically shows a tubular stent.
  • FIG. 3 schematically shows an embodiment of the barbs.
  • biodegradable is to be understood as meaning a property of the metal alloy, polymers or polymer mixtures that they can be biologically degraded in the human or animal body without endangering the health of humans or animals.
  • a valve-bearing, biodegradable, resorbable stent made of a metal alloy made of magnesium and rare earths in combination with a coating made of a polymer mixture.
  • the entire stent made of metal alloy and polymer coating is biodegradable, which in the context of the present disclosure refers to a chemical decomposition into smaller molecules, compounds or even elements through biological processes.
  • An example of a biodegradable polymer in the sense of the present disclosure is poly(DL-lactide-co-glycolide).
  • the structure of the stent is based on continuously arranged struts, which form so-called stent elements.
  • These stent elements can, for example, be rhombus-shaped, which in connection with the present invention can also be referred to as a diamond shape.
  • the struts of the stent can serve to attach heart valves.
  • the same number of Diamonds are available.
  • the number of diamonds in the circumference of a stent is therefore a number divisible by 3, preferably 24 or 21, and 18, 15 or 12 for stents with a smaller target diameter.
  • the number of strut elements divisible by 3 results from the fact that a three-leaf valve must be sewn in/attached, point-symmetrical to the center of the stent, with all valve leaflets being the same size. Each of the 3 leaflets therefore requires the same number of attachment struts.
  • a stent cut from a tube is manufactured with barbs (spikes) which serve to fix a heart valve (heart valve holder).
  • a stent comprises only one row of diamonds in the circumference, several rows of diamonds are arranged directly next to each other and connected to each other, or the diamonds are connected to each other in the circumference via struts.
  • Another element of the present invention are, in one embodiment, integrated barbs (so-called spikes), with the aid of which, for example, the heart valve consisting of pericardium is fixed in the stent.
  • integrated barbs so-called spikes
  • the invention is based on a fluoridated or non-fluoridated compound (alloy) of magnesium, transition metals, rare earths, for example from the group of lanthanides such as gadolinium, disprosium, yttrium, etc. in combination with a mixture of polymers.
  • a fluoridated or non-fluoridated compound (alloy) of magnesium, transition metals, rare earths for example from the group of lanthanides such as gadolinium, disprosium, yttrium, etc. in combination with a mixture of polymers.
  • Magnesium has a short resorption time.
  • a combination of a small amount of polymer on a framework consisting of magnesium and rare earths is proposed as the material for a stent according to the present disclosure in order to achieve a precisely adjustable resorption time.
  • the combination of magnesium and rare earths has proven to be advantageous with regard to the adjustability of the resorption time.
  • the stent consists of a framework which is formed by a net-like, for example diamond-shaped, structure made of a mesh of the metal-rare earth alloy which is coated with a polymer.
  • a net-like, for example diamond-shaped, structure made of a mesh of the metal-rare earth alloy which is coated with a polymer.
  • flattened metal struts are connected to one another in a diamond shape.
  • the struts of the stent elements are flattened and have recesses in the surface; the struts which Stent elements are therefore slotted.
  • a section of the honeycomb-like network structure made of struts is connected via lateral struts to another section of a diamond-shaped, honeycomb-like network structure, for example. This structure enables the size of the stent to be adjusted in both width and length depending on the intended application.
  • the structure of the stent is covered with a polymer coating.
  • the polymer coating ensures that the resorption time of the stent can be set to a defined period (3-6 months is the target).
  • the stent struts can have barbs with a diameter in the range of 20 to 50 pm. After cutting, polishing and coating the magnesium alloy polymer stent, the spikes are bent luminally (inwardly into the stent) at an angle of 45-90° and now protrude into the interior of the stent.
  • the stent After forming a heart valve from the body's own tissue, the stent can be pulled over the heart valve in a corresponding design. The barbs pierce the pericardium and anchor themselves there. The heart valve is anchored in the stent in this way without any further stitches, apart from a few safety stitches. Since sewing a heart valve into a stent normally takes up a large part of the production time of the heart valve stent (experience shows that between 40 and 60 minutes), the invention of the barbs saves valuable intervention time and thus anesthesia time for the patient.
  • a heart valve stent is delivered using a delivery system that includes a balloon catheter through which the Mg/rare earth/polymer stent can be anchored in children with congenital heart valve defects.
  • the stent according to the invention is a balloon-expandable stent, the struts of which can be slotted and filled with polymer. It is envisaged that the struts with polymer coating can be designed as double-T supports in order to achieve greater mechanical stability.
  • the shape of the stent is chosen depending on the location of use: For use in a pulmonary valve position, the stent is shaped in length and circumference For example, they can consist of diamond-shaped diamonds, although this shape is not mandatory. Each of the diamonds is connected to the neighboring diamonds at its four corner points. This means that all diamonds have a closed configuration (see FIG. 1 and FIG. 2). For use in the aortic valve position, an upper ring of diamonds is created (crown), followed by long, longitudinal, curved struts in the area of the commissures and a conical edge (skirt) made of two rows of diamonds in the area of the left ventricular outflow tract.
  • a stent with a large number of short struts and thus small diamonds is produced. All struts are connected to one another by a connector. This gives the stent a high radial force with little longitudinal shortening.
  • the stent according to the invention can be designed according to the respective requirements, which include, for example, a need for radial force, planned residence time, the required diameter.
  • An advantage of the invention is that the stent can be adapted to different requirements.
  • FIG. 3 shows schematically an embodiment of the barbs of a stent according to the invention.
  • a biodegradable stent according to the present invention can be used as a vascular support in various congenital heart defects, e.g. for opening a pulmonary atresia, for keeping a ductus arteriosus Botalli open, for keeping an aortic isthmus stenosis open, for creating a growth stimulus in hypoplastic pulmonary arteries (“artificial growth”).
  • stent according to the invention outside of cardiovascular medicine are conceivable, such as for example as esophageal stents, as ureter supports and in urethral valves.
  • the present invention also relates to a system comprising a device for implanting a stent as described above, together with the stent.
  • a device for implanting a stent as described above is described, for example, in the published German patent application with the file number DE 10 2013 224 298 A1 and comprises a device for the transluminal introduction and placement of a self-expanding stent, in particular a heart valve stent, in a hollow organ, wherein the stent is arranged in a compressed state at the distal end of a tubular, flexible implantation catheter, characterized in that it has a tubular outer catheter, a tubular inner catheter and a tubular ring-shaped helical tension spring arranged at least at the distal end of the implantation catheter between the outer catheter and the inner catheter, which supports the proximal end of the stent with its distal end, which unfolds at the implantation site by pulling the outer catheter back relative to the helical tension spring to rest against the hollow organ.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Prostheses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une endoprothèse biodégradable, résorbable, comprenant une structure constituée d'un alliage métallique de magnésium avec des métaux de transition et/ou des terres rares, la structure étant enrobée d'un polymère, et la structure enrobée comportant des entretoises d'éléments d'endoprothèse, l'endoprothèse pouvant être une endoprothèse à valves. La présente invention concerne également l'utilisation de l'endoprothèse sans valves, ou d'un système comprenant une endoprothèse correspondante à implanter dans le cas de malformations cardiaques congénitales en vue d'ouvrir une artère pulmonaire, de maintenir ouvert un canal artériel, de maintenir ouverte une sténose de l'isthme aortique pour stimuler la croissance dans des artères pulmonaires hypoplastiques, ou en tant qu'endoprothèse œsophagienne, ou en tant que support d'uretère.
PCT/EP2024/066599 2023-06-15 2024-06-14 Endoprothèse pour implantation Pending WO2024256657A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024305156A AU2024305156A1 (en) 2023-06-15 2024-06-14 Stent for implantation
CN202480039902.8A CN121358508A (zh) 2023-06-15 2024-06-14 用于植入的支架

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
LULU103154 2023-06-15
LU103154A LU103154B1 (de) 2023-06-15 2023-06-15 Stent für die implantation von herzklappen

Publications (1)

Publication Number Publication Date
WO2024256657A1 true WO2024256657A1 (fr) 2024-12-19

Family

ID=86851373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/066599 Pending WO2024256657A1 (fr) 2023-06-15 2024-06-14 Endoprothèse pour implantation

Country Status (4)

Country Link
CN (1) CN121358508A (fr)
AU (1) AU2024305156A1 (fr)
LU (1) LU103154B1 (fr)
WO (1) WO2024256657A1 (fr)

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4222610A1 (de) 1992-07-10 1994-01-13 Jansen Josef Dr Ing Stützgehäuse für Klappen- und Schließorgane
WO2000062708A1 (fr) 1999-04-15 2000-10-26 Mayo Foundation For Medical Education And Research Extenseur multisection
US20090312834A1 (en) 2008-06-16 2009-12-17 Boston Scientific Scimed, Inc. Continuous double layered stent for migration resistance
DE102008040786A1 (de) 2008-07-28 2010-02-04 Biotronik Vi Patent Ag Biokorrodierbares Implantat mit einer Beschichtung enthaltend eine wirkstofftragende Polymermatrix
WO2011000354A2 (fr) 2009-06-29 2011-01-06 Be Innovative Gmbh Endoprothèse valvulaire à implantation percutanée, dispositif de mise en place et procédé de production de cette endoprothèse valvulaire
US20110060401A1 (en) 2007-02-16 2011-03-10 Universität Zürich Tubular Supporting Prosthesis Capable of Growing
US20110076319A1 (en) * 2007-01-30 2011-03-31 Michael Orlowski Bioresorbable metal stent with controlled resorption
US20120290073A1 (en) 2011-05-13 2012-11-15 Abbott Cardiovascular Systems Inc. Bioabsorbable scaffolds made from composites
US20130236498A1 (en) * 2012-03-09 2013-09-12 Eric K. Mangiardi Biodegradable supporting device
US20130325102A1 (en) 2010-12-21 2013-12-05 Lifetech Scientific (Shenzhen) Co., Ltd. Absorbable Blood Vessel Stent
DE102013224298A1 (de) 2013-11-27 2015-05-28 Deutsches Herzzentrum Berlin Vorrichtung zum Implantieren eines selbstexpandierbaren Stents in ein Hohlorgan
WO2016055564A1 (fr) 2014-10-10 2016-04-14 Jotec Gmbh Système de prothèse vasculaire
WO2016071357A1 (fr) 2014-11-04 2016-05-12 Jotec Gmbh Système d'endoprothèse couverte modulaire
WO2016127542A1 (fr) 2015-02-10 2016-08-18 东莞颠覆产品设计有限公司 Échafaudage vasculaire expansible multicouche
WO2017204803A1 (fr) * 2016-05-25 2017-11-30 Q3 Medical Devices Limited Dispositif de support biodégradable
WO2019052610A1 (fr) 2017-09-13 2019-03-21 Universitätsklinikum Hamburg-Eppendorf Prothèse valvulaire implantable
US20210338422A1 (en) 2017-09-27 2021-11-04 W. L. Gore & Associates, Inc. Prosthetic valves with mechanically coupled leaflets

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4222610A1 (de) 1992-07-10 1994-01-13 Jansen Josef Dr Ing Stützgehäuse für Klappen- und Schließorgane
WO2000062708A1 (fr) 1999-04-15 2000-10-26 Mayo Foundation For Medical Education And Research Extenseur multisection
US20110076319A1 (en) * 2007-01-30 2011-03-31 Michael Orlowski Bioresorbable metal stent with controlled resorption
US20110060401A1 (en) 2007-02-16 2011-03-10 Universität Zürich Tubular Supporting Prosthesis Capable of Growing
US20090312834A1 (en) 2008-06-16 2009-12-17 Boston Scientific Scimed, Inc. Continuous double layered stent for migration resistance
DE102008040786A1 (de) 2008-07-28 2010-02-04 Biotronik Vi Patent Ag Biokorrodierbares Implantat mit einer Beschichtung enthaltend eine wirkstofftragende Polymermatrix
WO2011000354A2 (fr) 2009-06-29 2011-01-06 Be Innovative Gmbh Endoprothèse valvulaire à implantation percutanée, dispositif de mise en place et procédé de production de cette endoprothèse valvulaire
US20130325102A1 (en) 2010-12-21 2013-12-05 Lifetech Scientific (Shenzhen) Co., Ltd. Absorbable Blood Vessel Stent
US20120290073A1 (en) 2011-05-13 2012-11-15 Abbott Cardiovascular Systems Inc. Bioabsorbable scaffolds made from composites
US20130236498A1 (en) * 2012-03-09 2013-09-12 Eric K. Mangiardi Biodegradable supporting device
DE102013224298A1 (de) 2013-11-27 2015-05-28 Deutsches Herzzentrum Berlin Vorrichtung zum Implantieren eines selbstexpandierbaren Stents in ein Hohlorgan
WO2016055564A1 (fr) 2014-10-10 2016-04-14 Jotec Gmbh Système de prothèse vasculaire
WO2016071357A1 (fr) 2014-11-04 2016-05-12 Jotec Gmbh Système d'endoprothèse couverte modulaire
WO2016127542A1 (fr) 2015-02-10 2016-08-18 东莞颠覆产品设计有限公司 Échafaudage vasculaire expansible multicouche
WO2017204803A1 (fr) * 2016-05-25 2017-11-30 Q3 Medical Devices Limited Dispositif de support biodégradable
WO2019052610A1 (fr) 2017-09-13 2019-03-21 Universitätsklinikum Hamburg-Eppendorf Prothèse valvulaire implantable
US20210338422A1 (en) 2017-09-27 2021-11-04 W. L. Gore & Associates, Inc. Prosthetic valves with mechanically coupled leaflets

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZARTNER, P. ET AL., CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, vol. 70, no. 3, 2007, pages 407 - 414

Also Published As

Publication number Publication date
AU2024305156A1 (en) 2025-12-04
CN121358508A (zh) 2026-01-16
LU103154B1 (de) 2024-12-16

Similar Documents

Publication Publication Date Title
DE69908736T2 (de) Ballonexpandierbarer überzogener Stent
DE102005013547B4 (de) Aneurysmen-Stent und Verfahren zu seiner Herstellung
EP1270023B2 (fr) Stent métallique dégradable in vivo
DE60029925T2 (de) Stent mit vorrübergehenden haltebändern
DE60220319T3 (de) Sich auflösender stent
EP2117476B1 (fr) Prothèse de soutien tubulaire avec valvule cardiaque, notamment pour le remplacement de la valvule aortique
EP1648342B1 (fr) Endoprothèse vasculaire tressée destinée à être implantée dans un vaisseau sanguin
EP3302373B1 (fr) Support vasculaire
EP3203931B1 (fr) Système de prothèse vasculaire
EP2967934B1 (fr) Endoprothèse biorésorbable
EP0578998A1 (fr) Endoprothèse percutanée implantable
EP2809267A1 (fr) Prothèse vasculaire endoluminale
EP3630009B1 (fr) Endoprothèse à poches
EP2822514B1 (fr) Tuteur vasculaire à haute flexibilité présentant un point de rupture
DE10301850B4 (de) Stent
EP2846732A1 (fr) Prothèse vasculaire intraluminale à fenestration in situ
WO2024256657A1 (fr) Endoprothèse pour implantation
EP4169489A1 (fr) Stent
EP4169488A1 (fr) Stent
WO2019072912A1 (fr) Implant vasculaire expansible
EP1711213A1 (fr) Implant permettant de liberer une substance active dans un recipient traverse par un fluide corporel
EP2385806A1 (fr) Dispositif comportant un appareil pouvant être implanté dans un vaisseau du corps d'un patient et un revêtement et procédé de fabrication de ce dispositif
EP2446863A1 (fr) Stent doté d'un répartition asymétrique des forces

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24737337

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024305156

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024305156

Country of ref document: AU

Date of ref document: 20240614

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202517123190

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 202517123190

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2024737337

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024737337

Country of ref document: EP

Effective date: 20260115

ENP Entry into the national phase

Ref document number: 2024737337

Country of ref document: EP

Effective date: 20260115

ENP Entry into the national phase

Ref document number: 2024737337

Country of ref document: EP

Effective date: 20260115

ENP Entry into the national phase

Ref document number: 2024737337

Country of ref document: EP

Effective date: 20260115